Skip to Main Content

Paper Details

Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.
Ann Oncol
15
2023
Author NameAffiliation
Anders BjartellSkane University Hospital, Lund University
Byung Ha ChungYonsei University College of Medicine and Gangnam Severance Hospital
Kim N Chi
  • 1 - 3

Datasets

Release 1.2